R&D News | pharmaphorum

News

TIGIT underwhelms again as Novartis ducks out

The role of TIGIT as a target for immuno-oncology therapies has been called into question again after it was revealed that Novartis handed back rights to a drug partnered

News

Sensorion files to start trials of deafness gene therapy

French biotech Sensorion has filed its first regulatory application to start human testing of OTOF-GT, a gene therapy for one of the most common forms of congenital deafne

News

BMS takes option on Prothena Alzheimer’s drug in $2.2bn deal

Bristol-Myers Squibb has upgraded a long-running alliance with Prothena in Alzheimer’s disease, taking an option on a tau protein-targeting antibody in early-stage clinica

News

J&J snaps up Nanobiotix cancer radiotherapy in $2.5bn+ deal

Johnson & Johnson has bolstered its oncology pipeline by licensing a drug from Nanobiotix designed to enhance the effectiveness of radiotherapy for solid tumours.

News

FDA approves first progression-slowing Alzheimer's drug

Eisai's Leqembi, marketed by Biogen, secured full FDA regulatory approval as expected

News

FDA grants Priority Review of Astellas’ zolbetuximab BLA

Astellas Pharma Inc has announced that the US Food and Drug Administration (FDA) has accepted and granted Priority Review of its zolbetuximab Biologics License Application

TIGIT underwhelms again as Novartis ducks out

Sensorion files to start trials of deafness gene therapy

BMS takes option on Prothena Alzheimer’s drug in $2.2bn deal

J&J snaps up Nanobiotix cancer radiotherapy in $2.5bn+ deal

FDA approves first progression-slowing Alzheimer's drug

FDA grants Priority Review of Astellas’ zolbetuximab BLA

Precision medicine in action, with Cary Claiborne

How to meet your physicians where they are online

News

Editor's Picks